Neu REFIX β-glucan reduces muscle fibrosis in Duchenne muscular dystrophy MDX mice, in joint research with Dr. Yoshitsugu Aoki, NCNP, Tokyo, Japan.

Publication in Scientific Reports documents inflammation control as well.

News provided by

Oct. 18, 2023 14:50

공유
스크랩
인쇄
글자크기
Font Size
- ASmall
- AMedium
- ALarge
- AVery Large

TOKYO--(Business Wire / Korea Newswire)--Skeletal muscle fibrosis which leads to locomotor dysfunction in Duchenne Muscular Dystrophy (DMD) could be significantly reduced by oral consumption of Neu-REFIX beta 1,3-1,6 glucans alone for 45 days without any other drugs, in MDX mice model of DMD. This research was undertaken jointly with the team of Dr Yoshitsugu Aoki, Head, Dept. of Molecular Therapy, National Center for Neurology and Psychiatry (NCNP), Tokyo, Japan, a pioneer in developing solutions to DMD such as exon skipping therapy. The findings published in Scientific Reports, a publication by Nature portfolio also reported a reduction in muscle inflammation, which precedes fibrosis and muscle dysfunction, leading gradually to respiratory muscle failure followed by lung dysfunction, cardiac fibrosis, heart failure and premature death.

This study followed an earlier clinical trial involving 27 patients in two groups in which safety along with reduction of inflammation and fibrosis and increase in plasma dystrophin were confirmed in those who consumed the same neu REFIX Beta-glucans along with standard of care medications, compared to the control group who took only the standard of care medications. An important break-through in this animal study is that the treatment-arm group MDX mice consumed only the Neu-REFIX Beta glucans without any drugs, unlike the clinical study. Currently, for DMD there are no definitive and efficacious remedies available. Exon skipping therapy is available only to less than 30% of the patients with specific exon deletions and gene therapy may not be applicable to patients in the advanced stages of DMD. Going by our clinical experience, Neu-REFIX β-glucans are worth validating clinically for longer duration, both as a stand-alone option and also as an adjuvant to standard of care medications, in different sets of appropriate age groups of patients, opined Dr Raghavan, who has recently completed another clinical study of six-months duration wherein Neu-REFIX yielded improvement in 6MWT, NSAA & MRC.

With additional experiments in MDX mice underway, as more data evolves, that may be value adding to recommend Neu REFIX β-glucan to DMD patients, said Dr Yoshitsugu Aoki. Reduction of myocardial fibrosis in MDX mice and beneficial reconstitution of gut microbiome in clinical studies give us a hope that this allergen-free orally consumable and safe food supplement could become a worthy adjuvant to disease modifying treatments in DMD, said researchers who presented the data in World Muscle Society WMS 2023 and World Congress of Neurology WCN 2023.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231016033169/en/

Website: https://www.gncorporation.com/

Contact

GN CORPORATION CO. LTD.
Samuel JK Abraham
info@gncorporation.com

This news is a press release provided by GN Corporation Co., Ltd..

GN Corporation Co., Ltd. News Releases

Cell therapy for male urethral stricture: BEES-HAUS clinical application in Edogawa Hospital Japan, reports Dr. Akio Horiguchi in IMORU.

Urethral stricture affecting men of all ages, with increasing incidence after 55, is a recurring problem despite several treatment options. By transplanting autologous lab-engineered buccal tissue cells (BEES-HAUS ), Dr Akio Horiguchi successfully accomplished the first clinical transpl...

4월 1일 17:00

남성 요도 협착 세포 치료: IMORU의 호리구치 아키오 박사가 보고한 일본 에도가와 병원의 BEES-HAUS 임상 적용

모든 연령대의 남성에게 영향을 미치는 요도 협착은 55세 이후 발병 건수가 증가하며, 여러 치료 옵션이 있음에도 반복되는 문제이다. 실험실에서 공학적으로 가공한 자가 구강 점막 세포(BEES-HAUS )를 이식하여, 호리구치 아키오 박사(Dr Akio Horiguchi)가 일본 에도가와 병원에서 첫 번째 임상 이식을 일...

4월 1일 17:00

More News

GN Corporation Co., Ltd.

News Releases RSS Feed Website

국내 최대 배포망으로 보도자료를 배포하세요

지금 시작하기